VeraCity: The Psychedelic Frontier
VeraCity: The Psychedelic Frontier aired January 25 on Citytv. Dr. McIntyre speaks about research and treatments.
Read More
Challenges of parenting during the pandemic
Dr. Roger McIntyre on the challenges of parenting during COVID
Read More
A phone call may be all it takes to ease pandemic loneliness: study
TORONTO -- Give your friends and family a call, it may just ease the pandemic loneliness, depression and anxiety that are taking hold. A study published in the peer-reviewed journal JAMA Psychiatry suggests that phone calls can help people who are left feeling alone and isolated during the pandemic, no training required. This isn’t overly surprising, for humans have a basic need to connect with others, said Roger McIntyre, a psychiatry and pharmacology professor at the University of Toronto. “It speaks to the fact that as people, as human beings, we need to have contact. That is an undeniable fact. It’s in our DNA, years of evolution. We’re social organisms, we need contact,” McIntyre told CTVNews.ca in a phone interview on Wednesday. The study aimed to quickly address the issue of loneliness during the pandemic and focused on socially isolated adults who...
Read More
This is your brain on pandemic: What chronic stress is doing to us
Back in the 1980s, there was a public service announcement on TV that you may remember — or may have seen on YouTube. A guy in a kitchen held up an egg and said, "This is your brain." Then he cracked the egg into a hot frying pan, and said, "This is your brain on drugs." One year into this pandemic, your brain might be feeling a bit like that egg: Fried. "Everything is so much harder," said Stephanie Johnson, a client relationship executive who lives in Toronto. "I don't have the motivation that I used to have. I don't have the efficiency that I used to have." "Defeated" is how Vas Smountas, a freelance graphic designer, describes it. Also living in Toronto, she describes herself these days as "tired, defeated, foggy, unmotivated." And research suggests those feelings are not uncommon right now,...
Read More
Pandemic Parenting: Experts on Helping Children Get Past Their Germ Fear
TORONTO -- A year ago, many Canadians were washing down any package that came to the door. Now we’re tearing with abandon into that Amazon box before the masked delivery driver has even left the front porch. But for some, a year’s worth of timed handwashing and pushing crosswalk buttons with our elbows has caused significant stress that won’t be so easy to cast aside when the world turns back to normal. This is particularly true for children who are prone to anxiety. “Certainly (the pandemic) is causing significant distress in kids,” says Dr. Sandra Mendlowitz, a psychologist and co-founder of Reframe Psychology Clinic in Toronto, which focuses on anxiety disorders, depression and obsessive-compulsive disorder (OCD) in children. “Part of being a child is to have lots of social interactions and learn from that, so I think that it's kind...
Read More
The Current with Matt Galloway
Understanding pandemic burnout; why tackling deforestation could be key to stopping future viral outbreaks; Yukon enacts comprehensive transgender health care; and Canadian universities battling COVID-19 outbreaks Feeling tired? Unmotivated? You might be experiencing pandemic burnout. We discuss the impact of long-term stress on our brains and memory with Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, and Dr. Natasha Rajah, professor in the department of psychiatry at McGill University and the Douglas Research Centre in Montreal. Then, as this pandemic drags on, scientists are already looking at how to prevent the next one — and some say a key factor will be tackling deforestation. We discuss why with Dr. Jonathan Epstein, a veterinarian and disease ecologist; Kimberly Fornace, an epidemiologist at the London School of Hygiene and Tropical Medicine; and Terry Sunderland, a professor of...
Read MoreBraxia Scientific Announces CAD$3 Million Private Placement with Institutional Investors
TORONTO, ONTARIO – Jan. 6, 2022 – Braxia Scientific Corp. (the “Company” or “Braxia”), (CSE: BRAX) (FWB: 4960), a medical research company with clinics providing innovative psychedelic treatments for persons with depression and related disorders, is pleased to announce that it has entered into a securities purchase agreement with institutional investors for a private placement of its common shares (“Common Shares”) and warrants to purchase Common Shares (“Warrants”) for gross proceeds of approximately CAD$3 million (the “Private Placement”). Pursuant to the Private Placement, the Company will issue 30,000,000 Common Shares (or Common Share equivalents) and Warrants to purchase up to an aggregate of 30,000,000 Common Shares at a purchase price of CAD$0.10 per Common Share and associated Warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD$0.125 per Common Share for a...
Braxia Scientific Achieves Milestone as Landmark Psilocybin Clinical Trial Commences, Participants Receive First Doses of Psilocybin
Patients receive first dose in first-ever Health Canada-approved, multi-dose psilocybin clinical trial conducted at Braxia Scientific’s subsidiary CRTCE clinic Trial establishes psilocybin treatment framework for patients with TRD and opens new pathway for patients to access psychedelic treatment TORONTO, ONTARIO December 14th, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative psychedelic treatments for persons with depression and related disorders, has reached a milestone as the first Health Canada-approved multiple-dose psilocybin clinical trial which commenced with first patients dosed in November 2021. The trial, which is being sponsored by the Brain and Cognition Discovery Foundation, is being conducted at the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned Braxia subsidiary, and includes adults with treatment-resistant depression (TRD) as part of bipolar or...
Second Quarter 2022 Financial Results; Corporate Update
Braxia Scientific Reports Second Quarter 2022 Financial Results and Provides Corporate Update Expanded clinical infrastructure to support a growing portfolio of clinical trials of novel interventions and for drug discovery; 14 registered clinical trials in depression, led by Company CEO and Chief Medical and Scientific Officer, completed or in process Excellent progress on only psilocybin trial in Canada actively recruiting study participants to receive psilocybin-assisted therapy Clinical footprint in Canada has administered ~4,900 ketamine treatments to date; focus on expansion opportunities in the U.S. and Europe TORONTO, ONTARIO Nov. 29, 2021 – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal second-quarter results for the three-month period ending September 30,...
Advisory Board of KetaMD
Braxia Scientific CEO Dr. Roger McIntyre to Join Advisory Board of At-Home Telemedicine Platform KetaMD TORONTO, ONTARIO Nov. 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, is joining KetaMD as an adviser. KetaMD, currently in beta, is a telemedicine platform in development that aims to provide affordable, potentially life-changing at-home medical ketamine treatments guided by registered nurses over telemedicine. Dr. McIntyre is a world-renowned expert in the treatment of depression and has contributed extensively to clinical practice guidelines for ketamine. He has been involved in nearly 750 published research endeavours centered around the treatment of mental health disorders. Dr. McIntrye is also the lead author...
Keynote at Wonderland: Miami
Braxia Scientific CEO Dr. Roger McIntyre to Deliver Keynote Address at Wonderland: Miami TORONTO, Ontario Nov. 8, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is delighted to announce that its CEO, Dr. Roger McIntyre, has been selected to be a keynote speaker at the Wonderland: Miami conference. The two-day event, which is scheduled to begin Mon., Nov. 8 at the Adrienne Arsht Center for the Performing Arts of Miami-Dade County, will act as a launching pad for innovative companies connected to the psychedelic medicine space. Dr. McIntyre will discuss the challenges patients with medication-resistant mental health issues face in accessing ketamine and other psychedelic therapies as well as developing new therapies. He will also outline...
Graduates First Cohort of Medical Professionals
Braxia Scientific Graduates First Cohort of Medical Professionals From Psilocybin-Assisted Therapy Training Program; Ready to Start Health Canada Approved Psilocybin Clinical Trial TORONTO, ONTARIO November 2, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is excited to announce the completion of the training program for psilocybin-assisted clinical therapy by its first multi-disciplinary cohort of 20 qualified therapists from diverse psychiatry and psychotherapy backgrounds. This program was implemented by the Braxia Institute, the Company’s training centre focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy. Through this program, the Company is able to develop, train, and support qualified, independent medical physicians, psychologists and psychotherapists skilled in best practices to implement safe and...
Audio Webcast and Dial-In Number
Braxia Scientific Provides New Audio Webcast and Dial-In Number for Annual General Meeting TORONTO, ONTARIO, October 27, 2021 /CNW/ – Braxia Scientific Corp. (“Braxia Scientific”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today provides revised details in connection with its annual general meeting of shareholders to be held on October 28, 2021, at 10:00 am (EST). The Company advises that the audio webcast and dial-in number for shareholders wishing to listen to the meeting have been changed from those provided in the notice of annual general meeting and information circular of the Company. The updated audio webcast and dial-in number is below: Audio Webcast Link: Click here for secure access Phone Number: +1-844-974-2903 Meeting Number: 2345 – 825 – 5938 Password: meet2021 Access Code: 234 – 582...
Voting Results from the Annual General Meeting
Braxia Scientific Announces Voting Results from the Annual General Meeting of Shareholders TORONTO, ONTARIO October 29, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce the voting results from its Annual General Meeting of Shareholders held on Thursday, October 28, 2021. A total of 11.77% of the issued and outstanding common shares of the Company were represented either in person or by proxy at the meeting. The following 4 nominees proposed by the Company were elected as Directors of Braxia Scientific to serve until the Company’s next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:...
W5: Harnessing the Power of Psychedelic Drug Therapy
A W5 investigation into an unconventional treatment for severe depression and PTSD that involves the drug ketamine.
Braxia Scientific Featured in National News; W5
Braxia Scientific Featured in National News, W5 Canada’s Most-Watched Documentary Series, Providing Access and Promoting Use of Ketamine to Treat Brain-Based Illnesses TORONTO, ONTARIO October 22, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its inclusion in recent national and local news coverage of psychedelics to treat mental disorders. Braxia Scientific CEO Dr. Roger McIntyre will be featured on CTV’s W5, Canada’s most-watched current affairs and documentary program. The episode, entitled “Psychedelic Healing,” will air on Saturday, October 23, 2021, at 7 p.m. Eastern Standard Time (EST). Braxia Scientific and the Canadian Rapid Treatment Center of Excellence (CRTCE), a wholly owned subsidiary, are also highlighted in a recent article by Toronto Life, a monthly...
Journal of the Royal Society of Medicine
Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific CEO Dr. Roger McIntyre Journal of the Royal Society of Medicine Publishes New COVID-19 Suicide Research Led by Braxia Scientific CEO Dr. Roger McIntyre Findings Underscore Company Core Objectives to Develop Ketamine Derivatives as Additional Measures to Further Reduce Suicidality TORONTO, ONTARIO October 21, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce the publication of a new study led by Braxia Scientific CEO Dr. Roger McIntyre in the Journal of the Royal Society of Medicine. The publication, entitled “Suicide reduction in Canada during the COVID-19 pandemic: lessons informing national prevention strategies for suicide reduction” was initiated to evaluate...
NBA Champion Lamar Odom
Braxia Scientific CEO Dr. Roger McIntyre to Share Stage With NBA Champion Lamar Odom and ‘Psychedelic Concierge’ Zappy Zapolin to Discuss the Benefits of Ketamine Treatment for Mental Health Panel discussion on November 9 at Wonderland: Miami will review the benefits of ketamine treatment for depression and other mental health conditions TORONTO, ONTARIO October 14, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its CEO, Dr. Roger McIntyre, will join fellow VIPs Lamar Odom and Zappy Zapolin for a panel discussion entitled “Ketamine Treatment Goes Mainstream” at the Wonderland: Miami conference on November 9, 2021. The two-day event, which is scheduled to begin November 8 at the Adrienne Arsht Center for the Performing...
Encouraging Results of Ketamine Study
Braxia Scientific Reports Encouraging Results of Ketamine Study Showing Significant Reduction in Depressive Symptoms and Suicidality with Ketamine as a Solo Treatment TORONTO, ONTARIO Sept. 30, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to report encouraging preliminary findings of a recent clinical study that suggests ketamine may be as effective as a standalone antidepressant, versus as an adjunctive therapy. The study, which was conducted at the Canadian Rapid Treatment Centre of Excellence (CRTCE), a wholly owned Braxia subsidiary, showed comparable clinical benefits (e.g., antidepressant effects and reduction in suicidal thoughts) in a large sample of 220 patients with treatment-resistant depression (TRD) who received intravenous (IV) ketamine infusions as a monotherapy, as compared with those receiving...
Canaccord Genuity
Canaccord Genuity 41st Annual Growth Conference Registration for Canaccord Genuity 41st Annual Growth Conference Click here Symbols – CSE: BRAX OTC: BRAXF FWB: 496
Global Investment Conference
H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Registration for H.C. Wainwright 23rd Annual Global Investment Conference – September 13-15, 2021 Click here Symbols – CSE: BRAX OTC: BRAXF FWB: 496
First Quarter 2022 Financial Results
Braxia Scientific Reports First Quarter 2022 Financial Results; Company Achieves 80% Revenue Growth from Expanding Clinic Patient Base Revenue from four Canadian clinics increased 80.3% to $407,075 year-over-year Exceeding monthly IV Ketamine infusion targets, ramping up infusions at new Montreal clinic Advancing three funded clinical trials through Braxia Scientific’s network of clinics, including a Ketamine trial for Bipolar Depression, a Ketamine trial to rapidly reduce suicidality, and the first multiple-dose psilocybin trial to combat treatment-resistant depression TORONTO, ONTARIO Aug. 30, 2021 – Braxia Scientific Corp. (“Braxia Scientific,” or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, today announced the filing of its fiscal first-quarter results for the three-month period ending June 30, 2021. Complete financial statements along with related management discussion and analysis can be...
Landmark Clinical Trial
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...
CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT CANACCORD GENUITY 2021 ANNUAL GROWTH CONFERENCE AUGUST 10-12 TORONTO, ONTARIO Aug. 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Canaccord Genuity Annual Growth Conference. The conference will be held virtually on August 10-12, 2021. Braxia Scientific CEO Dr. Roger McIntyre will deliver a presentation on the company’s initiatives related to developing novel therapeutics and delivery systems for treating depression and other brain-based disorders, as well as its administration of patient care in its network of clinics. Presentation Details: Date: Tuesday, August 10, 2021 Time: 11:30 a.m. ET Event Registration: https://bit.ly/3josIt3 For additional information on the conference, please CLICK HERE. About Braxia Scientific Corp. Braxia Scientific is a...
CORPORATE UPDATE AND REPORTING
BRAXIA SCIENTIFIC PROVIDES CORPORATE UPDATE AND REPORTS FISCAL FOURTH QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS TORONTO, ONTARIO July 30, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), today announced the filing of its fiscal fourth-quarter and year-end results for the three- and 12-month periods ending March 31, 2021. Complete financial statements along with related management discussion and analysis can be found in the System for Electronic Document Analysis and Retrieval (SEDAR), the electronic filing system for the disclosure documents of issuers across Canada at www.SEDAR.com. Through its global leading researchers and experienced implementation team, Braxia Scientific has established its presence in the mental health industry. Braxia Scientific successfully expanded its network of multidisciplinary clinics to four in 2021, with one of very few private clinics approved in Canada to provide innovative intravenous (IV) Ketamine treatments to...
EXPERIMENTAL MEDICINE IN PSYCHIATRY
BRAXIA SCIENTIFIC TO DISCUSS PSYCHIATRIC TREATMENT DISCOVERY AND DEVELOPMENT WITH OXFORD UNIVERSITY RESEARCHERS AT AIMDAY EXPERIMENTAL MEDICINE IN PSYCHIATRY ON JULY 7, 2021 TORONTO, ONTARIO July 7, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research and development company along with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Academic Industry Meeting Day (AIMday) on “Experimental Medicine in Psychiatry,” hosted by Oxford University on Wednesday, July 7, 2021. Braxia CEO Dr. Roger McIntyre will engage with Oxford scientists on the question of “How can we advance treatment discovery and development in psychiatry targeting cognition?” They will describe how research will be conducted with ketamine and psychedelics that integrates machine-learning, proof-of-mechanism research and implementation science which will be critical for the...
PSYCH INVESTOR SUMMIT
BRAXIA SCIENTIFIC ANNOUNCES PARTICIPATION AT PSYCH INVESTOR SUMMIT ON JULY 7, 2021 TORONTO, ONTARIO July 6, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming PSYCH Investor Summit: Research & Development. The conference will be held virtually on July 7, 2021. Braxia CEO Dr. Roger McIntyre will deliver a presentation discussing the recently announced funding by the Canadian Institutes Of Health Research (CIHR), of the Government of Canada, to support the first of its kind Ketamine clinical trial for Bipolar Depression. Additionally, Dr. McIntyre will discuss Braxia’s initiatives related to developing innovative therapeutics and delivery systems, while also administering patient care in its growing network of clinics. The presentation will...
Quebec Curfew May Increase Feelings of Loneliness: Psychiatrist
TORONTO -- Sparked by an explosion of COVID-19 cases, Quebec’s month-long curfew could increase people’s feelings of loneliness, one expert warned, urging people to maintain personal connections and physical activity. “People are getting fed up with the uncertainty.” Roger McIntyre, a psychiatry and pharmacology professor from the University of Toronto, told CTV News Channel on Sunday. McIntyre understands how maddening it must be for Quebecers to contend with yet another measure when they are already facing economic strife under COVID-19 public health restrictions.